Ardelyx (ARDX)
(Delayed Data from NSDQ)
$6.86 USD
+0.08 (1.18%)
Updated May 31, 2024 04:00 PM ET
After-Market: $6.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Ardelyx, Inc. [ARDX]
Reports for Purchase
Showing records 141 - 160 ( 171 total )
Company: Ardelyx, Inc.
Industry: Medical - Drugs
EoP2 Meeting Provides Clear Path for Tenapanor in Hyperphosphatemia, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
1Q, Key Catalysts Up Ahead, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
4Q15 Results, ARDX''s Late-Stage Pipeline Opportunity is Underappreciated, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
After a Rough Start, Opportunities Begin to Stand Out
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
RDX022 PD Data Encouraging, Ph 3 Hyperkalemia Study Teed Up for 2H16, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Tenapanor and RDX022 Development Accelerates, Reiterate OP and $24 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Regains Rights to RDX002; Removing Milestone Payments from Our Model, Reiterating $24 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
2Q15 EPS, RDX022 Could Have Near-Term Promise in Hyperkalemia, Reiterate OUTPERFORM Rating and Raising PT to $24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Investor Day Recap: Development Strategy for Tenapanor and Other Pipeline Candidates Highlighted, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Regains Rights to Tenapanor and Related Compounds
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
ARDX Regains Rights to Tenapanor and Related Compounds; Raises $77.8M; Trimming Price Target to $19 From $22, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Q1:15 EPS; Well Capitalized Ahead of Key Partnership Decision for Tenapanor
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
CKD Study Misses Primary Endpoint, but Data Further Confirms Tenapanor Benefit in ESRD and IBS-C,
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 6th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Company: Ardelyx, Inc.
Industry: Medical - Drugs
4Q14 Earnings, Oversold Shares Provides Attractive Entry Point, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Releases Additional Data from Phase IIb ESRD Trial, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
Releases Additional Data from Phase IIb ESRD Trial, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ardelyx, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L